{"filing":{"accession_number":"0001140361-26-040509","cik":"0001708688","ticker":"IFRX","company_name":"InflaRx N.V.","form":"6-K","filing_date":"2026-10-22","report_date":"2026-10-22","primary_document":"ef20084212_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1708688/000114036126040509/ef20084212_6k.htm"},"events":[{"id":37198,"run_id":34295,"accession_number":"0001140361-26-040509","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This exhibit is a press release announcing presentation of pre-clinical data on izicopan at Kidney Week 2026, demonstrating the drug's therapeutic potential in renal disease models. The disclosure highlights new structural modeling insights and positive efficacy signals in two kidney injury models (IRI and UUO), supporting advancement toward clinical development in ANCA-associated vasculitis and additional renal indications. While this is a research milestone rather than a discrete corporate event (M\u0026A, executive change, financial obligation), it represents material operational progress on the company's lead program that would affect a reasonable investor's assessment of development trajectory and competitive positioning.","company_name":"InflaRx N.V.","ticker":"IFRX","filing_date":"2026-10-22","form":"6-K","submitted_at":null,"items":[{"id":41834,"accession_number":"0001140361-26-040509","item_number":"EX-99.1","item_title":"ef20084212_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a press release announcing presentation of pre-clinical data on izicopan at Kidney Week 2026, demonstrating the drug's therapeutic potential in renal disease models. The disclosure highlights new structural modeling insights and positive efficacy signals in two kidney injury models (IRI and UUO), supporting advancement toward clinical development in ANCA-associated vasculitis and additional renal indications. While this is a research milestone rather than a discrete corporate event (M\u0026A, executive change, financial obligation), it represents material operational progress on the company's lead program that would affect a reasonable investor's assessment of development trajectory and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-22T20:07:01.751431+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41834,"accession_number":"0001140361-26-040509","item_number":"EX-99.1","item_title":"ef20084212_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a press release announcing presentation of pre-clinical data on izicopan at Kidney Week 2026, demonstrating the drug's therapeutic potential in renal disease models. The disclosure highlights new structural modeling insights and positive efficacy signals in two kidney injury models (IRI and UUO), supporting advancement toward clinical development in ANCA-associated vasculitis and additional renal indications. While this is a research milestone rather than a discrete corporate event (M\u0026A, executive change, financial obligation), it represents material operational progress on the company's lead program that would affect a reasonable investor's assessment of development trajectory and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-22T20:07:01.751431+00:00","company_name":"InflaRx N.V.","ticker":"IFRX","filing_date":"2026-10-22"}]}